Target Name: ETNPPL
NCBI ID: G64850
Review Report on ETNPPL Target / Biomarker Content of Review Report on ETNPPL Target / Biomarker
ETNPPL
Other Name(s): Ethanolamine-phosphate phospho-lyase | alanine--glyoxylate aminotransferase 2-like 1 | ethanolamine-phosphate phospho-lyase | ETNPPL variant 1 | AT2L1_HUMAN | Ethanolamine-phosphate phospho-lyase, transcript variant 1 | Alanine--glyoxylate aminotransferase 2-like 1 | AGXT2L1 | Ethanolamine-phosphate phospho-lyase (isoform 1) | Alanine-glyoxylate aminotransferase 2-like 1

ETNPPL: A Key Enzyme in The Metabolism of Ethanolamines

ETNPPL (Ethanolamine-phosphate phospho-lyase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key enzyme in the metabolism of ethanolamines, which are naturally occurring compounds that are found in many foods, such as alcohol, beer, and wine. ETNPPL is responsible for breaking down these ethanolamines into simpler compounds, which are then excreted from the body.

The Importance of ETNPPL

ETNPPL is a critical enzyme that helps regulate the levels of ethanolamines in the body. When ethanolamines are consumed, they are broken down into their simpler compounds through the action of ETNPPL. This process is essential for maintaining the health and function of the brain and other organs.

ETNPPL is also involved in the metabolism of many other compounds, including amino acids, neurotransmitters, and drugs. It is a key enzyme in the metabolism of many drugs, including those used to treat alcoholism and other disorders.

Drug Target or Biomarker?

The discovery of ETNPPL as a potential drug target or biomarker has significant implications for the treatment of many disorders. ETNPPL is a target that has been targeted by researchers for its potential to treat alcoholism, Parkinson's disease, and other disorders.

In the context of alcoholism, ETNPPL has been shown to play a key role in the metabolism of alcohol and the development of alcohol tolerance. Studies have shown that individuals with alcoholism have lower levels of ETNPPL than those without the disorder. By activating ETNPPL, researchers have been able to increase the amount of alcohol metabolism enzymes in the brain, which can help break down alcohol and reduce the risk of alcohol-related complications.

In addition to its potential as a treatment for alcoholism, ETNPPL has also been targeted for its potential to treat Parkinson's disease. Parkinson's disease is a neurodegenerative disorder that is characterized by the loss of brain cells that control movement and other functions. ETNPPL has been shown to play a role in the metabolism of the neurotransmitter dopamine, which is often affected in Parkinson's disease.

ETNPPL has also been shown to be involved in the metabolism of other drugs used to treat psychiatric disorders, such as antidepressants and antipsychotics. By activating ETNPPL, these drugs can be metabolized more quickly and efficiently, which can help reduce the risk of adverse effects and increase their effectiveness.

Conclusion

In conclusion, ETNPPL is a protein that is expressed in various tissues throughout the body and is involved in the metabolism of many different compounds, including ethanolamines and other drugs. Its potential as a drug target or biomarker has significant implications for the treatment of many disorders, including alcoholism and Parkinson's disease. Further research is needed to fully understand the role of ETNPPL in the treatment of these disorders and to develop safe and effective treatments.

Protein Name: Ethanolamine-phosphate Phospho-lyase

Functions: Catalyzes the pyridoxal-phosphate-dependent breakdown of phosphoethanolamine, converting it to ammonia, inorganic phosphate and acetaldehyde

The "ETNPPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETNPPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ETS1 | ETS2 | ETS2-AS1 | ETV1 | ETV2 | ETV3 | ETV3L | ETV4 | ETV5 | ETV6 | ETV7 | Eukaryotic translation initiation factor 2-alpha kinase | Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3